Helena H. Chaye
Directeur Général chez Western Oncolytics Ltd.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Richard Jones | M | 72 |
Western Oncolytics Ltd.
Western Oncolytics Ltd. Pharmaceuticals: MajorHealth Technology Western Oncolytics Ltd. develops novel therapies for cancer. The private company is based in Westlake. Helena H. Chaye has been the CEO of the American company since 2019.
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | - |
Grant McFadden | M | - |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | 1 ans |
Stephen H. Thorne | M | - |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | - |
Tom Leonard | M | - |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | - |
Terry Hermiston | M | - |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | - |
Jon Wigginton | M | 62 |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | - |
Kurt Rote | M | - |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 7 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Helena H. Chaye
- Réseau Personnel